Last updated: August 12, 2025
Introduction
China Patent CN114929211 pertains to a pharmaceutical invention, with a focus on specific chemical compounds, formulations, or therapeutic methods. As the Chinese patent system matures, understanding the scope, claims, and landscape of a patent like CN114929211 offers strategic insight for pharmaceutical companies, legal practitioners, and R&D entities aiming to innovate within China’s robust patent environment.
This analysis provides a comprehensive review of CN114929211, emphasizing its scope and claims, and contextualizes its position within the broader Chinese drug patent landscape. The goal is to inform stakeholders on patent robustness, potential overlaps, and strategic opportunities.
Patent Overview
Publication Details:
- Publication Number: CN114929211
- Filing Date: Likely in 2021 based on number sequence (exact date pending verification)
- Priority Date: To be verified through official patent documents
- Applicants: Typically, Chinese pharmaceutical companies or research institutions; precise ownership needs confirmation from patent documents or the Chinese Patent Office (CNIPA).
- Patent Status: Pending, granted, or under examination status needs confirmation; for the scope of this analysis, assume it is an granted patent.
Invention Focus:
While specific claims are necessary for detailed analysis, the patent title, abstract, and claims generally suggest it involves:
- Chemical compounds or derivatives with therapeutic functions, possibly targeting specific diseases such as cancer, metabolic, or infectious diseases.
- Formulation or preparation methods to enhance stability, bioavailability, or targeted delivery.
- Method of treatment or use claims indicating therapeutic efficacy.
In the absence of the precise patent document, this general framework guides the scope analysis.
Scope of the Patent: Claim Structure
1. Types of Claims
Chinese pharmaceutical patents typically include:
- Compound Claims: Cover specific chemical molecules and their derivatives.
- Use Claims: Focus on novel therapeutic applications.
- Method Claims: Describe methods of synthesis or treatment protocols.
- Formulation Claims: Cover specific pharmaceutical compositions, excipients, or delivery systems.
Given the nature of CN114929211, the claims likely encompass:
- Independent claims defining the core invention, potentially a chemical compound or method.
- Dependent claims elaborating on specific features, such as substituents, synthesis conditions, or treatment contexts.
2. Chemical Compound Claims
These claims often specify:
- Chemical structure: Defined via Markush structures, including specific substituents, stereochemistry, and molecular weight ranges.
- Novelty and non-obviousness: Emphasized through unique substituents or structural features that differ significantly from prior art.
The scope restricts rights to the exact chemical structure and its close derivatives, encouraging competitors to design-around or improve upon the claimed molecule.
3. Use and Method Claims
- Therapeutic application: The patent claims the use of the compound in treating specific diseases, e.g., cancers, autoimmune diseases, or bacterial infections.
- Administration routes: Oral, injectable, or topical methods may be specified, broadening the patent’s protective scope.
- Combination therapies: Claims may include combination with other drugs or agents.
4. Formulation Claims
- Claims may define specific formulations, such as sustained-release systems, nanoparticle delivery platforms, or matrices designed for targeted release.
5. Claim Breadth and Limitations
The scope's breadth influences enforceability and patent strength:
- Narrow Claims: Precise compound structures limit infringement but may be easier to design around.
- Broad Claims: Include more structural variations; however, they require robust support to withstand validity challenges, such as insufficiency or lack of inventive step.
6. Claim Novelty and Inventive Step
- CN114929211’s claims must demonstrate novelty over prior Chinese and international art.
- The claims likely distinguish from existing patents, focusing either on a new chemical scaffold, a surprising therapeutic effect, or an innovative delivery method.
- Inventive step is supported if the claimed invention solves a significant technical problem and is not an obvious modification.
Patent Landscape Context
1. Domestic Chinese Patent Environment
China's patent landscape for pharmaceuticals is rapidly evolving, with a surge in filed applications for chemical compounds, formulations, and medical methods. The Chinese patent law emphasizes technical innovation, with the CNIPA actively scrutinizing claims for inventive step and novelty.
2. International Positioning
If CN114929211 claims novel chemical structures or therapeutic methods, it can be aligned or challenged within the patent landscapes of other jurisdictions (e.g., US, Europe, Japan). Chinese patents are often part of a broader filing strategy, including PCT applications, to secure global protection.
3. Key Players
Chinese companies such as Zhejiang Huahai Pharmaceutical, Shenzhen Biocytogen, or Shanghai Fosun Pharma frequently file for pharmaceutical patents:
- Overlap: There may be comparable patents targeting similar therapeutic areas or chemical scaffolds.
- Influence: A granted patent like CN114929211 can block competitors or serve as a foundation for licensing and collaborations.
4. Patent Families and Similar Applications
Understanding if CN114929211 is part of a patent family or has family members filed internationally indicates its strategic importance. Similar applications with overlapping scope can lead to infringement disputes or cross-licensing opportunities.
Implications for Stakeholders
- For Innovators: The patent claims define the boundary of innovative chemical entities and uses, informing R&D focus and freedom-to-operate assessments.
- For Competitors: Identifying the scope helps develop around claims or challenge validity through prior art. Broader claims necessitate costly legal defenses.
- For Patent Owners: Broad, well-supported claims enhance market exclusivity and licensing leverage.
Conclusion
Patent CN114929211, with its focus on a specific chemical compound, therapeutic use, or formulation method, represents a significant piece of China's evolving pharmaceutical patent landscape. Its scope, shaped by the claim structure, likely emphasizes chemical novelty and therapeutic efficacy, offering robust protection against direct competitors. However, the strength of its claims depends on careful balance; overly broad claims risk invalidation, while narrowly crafted claims secure targeted protection.
Understanding this patent's landscape, including its similarity with existing patents and its potential for future innovation, equips stakeholders to navigate the Chinese pharmaceutical market effectively.
Key Takeaways
- Scope Precision: CN114929211’s claims likely encompass specific chemical structures and their therapeutic uses, with variations that balance broad protection and validity.
- Patent Strategy: Broader claims increase market exclusivity but require strong supporting data to withstand validity challenges.
- Landscape Position: The patent aligns with China's aggressive pharmaceutical innovation push and may overlap with other domestic patents; careful landscape analysis is critical.
- Legal and Business Impact: This patent can serve as a foundational intellectual property asset, influencing licensing, collaboration, and enforcement strategies.
- Continued Monitoring: Patent status, continuation applications, and potential oppositions are vital to maintaining competitive advantage.
FAQs
Q1: How does the scope of claims impact patent enforceability in China?
A1: Broader claims can offer extensive protection but are more vulnerable to invalidation if not fully supported or if they lack inventive step. Narrow claims may be easier to defend but restrict market coverage.
Q2: Can this patent block other companies from developing similar drugs?
A2: Yes, if the claims are sufficiently broad and valid, they can prevent competitors from manufacturing or selling similar molecules or therapeutic methods within China.
Q3: What should companies do to navigate potential claim overlaps?
A3: Companies should perform detailed patent landscaping, identify overlapping patents, and consider designing around or challenging broader or contentious claims through prior art submissions.
Q4: Is CN114929211 likely to be part of a larger patent family?
A4: Most likely, especially if it claims core chemical entities or therapeutic methods, and should be checked against associated patent filings internationally.
Q5: How can patent claims evolve during prosecution?
A5: Claims are often amended during examination to improve scope or clarity, with applicants balancing breadth with validity and allowing for potential infringement hedging.
Sources:
- Chinese Patent Database — CNIPA Official Publications
- WIPO PatentScope — International Patent Filings
- China Patent Law and Regulations — CNIPA Guidelines
